Report cover image

Global Cancer Gene Therapy Market Growth, Size, Trends Analysis - By Product, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published May 19, 2025
Length 255 Pages
SKU # SPER20187007

Description

Global Cancer Gene Therapy Market Introduction and Overview

According to SPER market research, ‘Global Cancer Gene Therapy Market Size- By Product, By End Use – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Cancer Gene Therapy Market is predicted to reach 26.62 billion by 2034 with a CAGR of 19.16%.

Cancer gene therapy is a cutting-edge treatment strategy that focuses on altering or engineering a patient’s genetic material to combat cancer. This approach may involve repairing faulty genes, activating genes that suppress tumor growth, or inserting new genes to boost the immune system’s ability to detect and eliminate cancer cells. By directly targeting the genetic basis of cancer, gene therapy offers a more precise and potentially less harmful alternative to conventional treatments such as chemotherapy and radiation.

Restraints:

The cancer gene therapy market encounters several significant challenges that may limit its broad adoption and advancement. A primary concern is the high cost associated with research, development, and treatment, which can make these therapies unaffordable for many and strain healthcare systems. Moreover, navigating complex regulatory frameworks and prolonged approval timelines often delays the introduction of new therapies.

Scope of the report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Product Therapy, By End Use

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Abeona Therapeutics Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio Inc., BioCancell Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux Corporation, GenVec, Introgen Therapeutics Inc., and OncoGenex Pharmaceuticals Inc.

Global Cancer Gene Therapy Market Segmentation:

By Product Therapy: Based on the Product Therapy, Global Cancer Gene Therapy Market is segmented as; Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer.

By End Use: Based on the End Use, Global Cancer Gene Therapy Market is segmented as; Research Institutes, Biopharmaceutical Companies, Diagnostic Centers, Others.

By Region:

This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

255 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Cancer Gene Therapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Cancer Gene Therapy Market
7. Global Cancer Gene Therapy Market, By Product Therapy 2021-2034 (USD Million)
7.1. Oncolytic Virotherapy
7.2. Gene Induced Immunotherapy
7.3. Gene Transfer
8. Global Cancer Gene Therapy Market, By End Use 2021-2034 (USD Million)
8.1. Research Institutes
8.2. Biopharmaceutical Companies
8.3. Diagnostic Centers
8.4. Others
9. Global Cancer Gene Therapy Market, 2021-2034 (USD Million)
9.1. Global Cancer Gene Therapy Market Size and Market Share
10. Global Cancer Gene Therapy Market, By Region, 2021-2034 (USD Million)
10.1. Asia-Pacific
10.1.1. Australia
10.1.2. China
10.1.3. India
10.1.4. Japan
10.1.5. South Korea
10.1.6. Rest of Asia-Pacific
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. United Kingdom
10.2.6. Rest of Europe
10.3. Middle East and Africa
10.3.1. Kingdom of Saudi Arabia
10.3.2. United Arab Emirates
10.3.3. Qatar
10.3.4. South Africa
10.3.5. Egypt
10.3.6. Morocco
10.3.7. Nigeria
10.3.8. Rest of Middle-East and Africa
10.4. North America
10.4.1. Canada
10.4.2. Mexico
10.4.3. United States
10.5. Latin America
10.5.1. Argentina
10.5.2. Brazil
10.5.3. Rest of Latin America
11. Company Profile
11.1. Abeona Therapeutics Inc.
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Asklepios BioPharmaceutical Inc.
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Altor Bioscience Inc.
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Bluebird bio Inc.
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. BioCancell Inc.
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. CelgeneInc.
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Elevate BioInc.
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. GlaxoSmithKlineInc.
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. Genelux Corporation
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. GenVec
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Introgen TherapeuticsInc.
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments
11.12. OncoGenex Pharmaceuticals Inc.
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments
11.13. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us